American Oncology Network Strengthens Team with Key Leadership Appointments
May 06, 2021 19:00 ET | American Oncology Network
Fort Myers, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology...
Aprea logo 445pt.png
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
May 06, 2021 16:15 ET | Aprea Therapeutics
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Kura Oncology Logo
Kura Oncology Reports First Quarter 2021 Financial Results
May 06, 2021 16:04 ET | Kura Oncology, Inc.
– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:04 ET | Harpoon Therapeutics
Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors ...
RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
May 05, 2021 10:50 ET | Curium
St. Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN)...
Neoleukin.png
Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial
May 05, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
May 05, 2021 02:30 ET | Curium
St. Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN)...
4D-Path_logo_rgb_full-color.jpg
World-Renowned Cancer Oncologist, Health Consultant and Entrepreneur Dr. Nelson Teich Added to 4D Path’s Distinguished Advisory Board
May 04, 2021 10:00 ET | 4D Path
NEWTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Dr. Nelson Teich, MD,...
TuftsCSDD-Logo-Color.jpg
Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Clinical Trials, According to Tufts Center for the Study of Drug Development
May 04, 2021 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Increasing complexity of clinical trials targeting cancer—including use of more sophisticated scientific designs, larger global scope, and greater focus on...
arvinas logo.jpg
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 04, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...